skip to Main Content

bm|t: Successful start in 2018

  • 2018

bm‑t is pleased to announce that seven of its investee part­ners have already closed financ­ing rounds in 2018. Over 10M EUR was raised by Biano GMP, ifesca, JenID, Mas­ter­PIM, OnCG­nos­tics, Pre­ven­ti­cus, and SiOp­tica, secur­ing the nec­es­sary financ­ing for impor­tant, value-dri­ving advancements.

These invest­ment rounds con­tin­ued the strong momen­tum from 2017, in which over 150M EUR was raised by 21 of bm‑t´s investee part­ners. Kevin Reeder, CEO of bm‑t sees the con­tin­u­a­tion of the fund rais­ing momen­tum as a great sign for Thürin­gen and a strong sig­nal to the invest­ment com­mu­nity of the attrac­tive­ness of invest­ing in the region. “With two very suc­cess­ful and highly-pub­li­cized exits last year – a sale to Face­book and a Nas­daq IPO – bm‑t has appeared on many investor´s radar screens. We are wit­ness­ing ever greater inter­est in co-invest­ments with bm‑t here in Thürin­gen, which will serve us well as we strive to cat­alyze the next Thürin­gen Champions.”

Of par­tic­u­lar note was that two of the 2018 financ­ings attracted mul­ti­ple mil­lion Euros from out­side of Ger­many, with one invest­ment com­ing from Switzer­land and another from Bel­gium. “We know that our com­pa­nies have impact­ful inno­va­tions and great sub­stance, and we are delighted to see that other investors out­side of Ger­many have rec­og­nized this and will now work with us as co-investors to help drive these com­pa­nies for­ward,” said Reeder.


About Biano GMP

BianoGMP was founded in August 2017 with the aim of being a GMP ser­vice provider for small to medium batch sizes in the field of oligonu­cleotides. By offer­ing out­sourced small and medium sized batch pro­duc­tion, BianoGMP will allow early-stage biotech com­pa­nies to reduce costs and shorten their devel­op­ment time­lines. The com­pany is also devel­op­ing meth­ods to offer a wide-range of oligo devel­op­ment and pro­duc­tion capabilities.

More infor­ma­tion about BianoGMP can be found under:


About ifesca

Founded 2016 in Ilme­nau, ifesca offers AI-based deci­sion sup­port solu­tions and ser­vices for the energy mar­ket. High-qual­ity fore­casts for energy-related time-series and opti­mized oper­a­tion sched­ules for energy pro­duc­tion are pro­vided through a spe­cial­ized IoT-plat­form ifesca.AIVA. The “as a Service”-solutions of ifesca mas­sively help to auto­mate deci­sion processes, thus increas­ing the qual­ity of fore­cast and reduc­ing man­ual efforts and process com­plex­ity. The ser­vices are pro­vided for any par­tic­i­pant of the global energy mar­kets. Work­ing in these mar­kets for over 15 years and its sci­en­tific back­ground enable the ifesca-team to cre­ate its unprece­dented AI-solutions.

More infor­ma­tion about ifesca can be found under:;


About JenID

jenID Solu­tions offers flex­i­ble soft­ware solu­tions to cus­tomers in finan­cial ser­vices, insur­ance, car rental, telecom­mu­ni­ca­tion and more indus­tries that are tai­lored to their needs and that allow them to per­form secure iden­tity checks any­where in the world in real-time. As such, the com­pany knows who is access­ing, using or bor­row­ing its prod­ucts. jenID thus con­tributes to the pro­tec­tion of end users› iden­ti­ties and pre­vents fraud.

More infor­ma­tion about jenID Solu­tions can be found under:


About Mas­ter­PIM

Mas­ter­PIM devel­opes browser-based tools for effi­cient prod­uct-infor­ma­tion-man­age­ment (PIM) sys­tems. The mod­u­lar design allows for easy data con­ver­sion with­out project man­age­ment and labo­ri­ous inte­gra­tion. Thus, per­mit­ting a fully-scal­able solu­tion for large mar­ket­places and man­u­fac­tur­ers alike. Mas­ter­PIM works with stan­dard­ized prod­ucts in order to cre­ate a seam­less onboard­ing process.

More infor­ma­tion about Mas­ter­PIM can be found under:


About OnCG­nos­tics

oncg­nos­tics GmbH is a spin-off from the uni­ver­sity women’s hos­pi­tal Jena and was founded early in 2012. As a mol­e­c­u­lar diag­nos­tic com­pany oncg­nos­tics is spe­cial­ized on can­cer diag­nos­tics. Oncg­nos­tics tests tar­get epi­ge­netic changes, so-called DNA methy­la­tions, that typ­i­cally occur in can­cer cells. The patented bio­mark­ers which are eval­u­ated using a spe­cific algo­rithm are the core of the prod­ucts and pro­vide thus the basis for the company’s activities.

More infor­ma­tion about oncg­nos­tics can be found under


About Pre­ven­ti­cus

Pre­ven­ti­cus turns your smart phone into a med­ical mea­sur­ing instru­ment, enabling users to per­form med­ical check­ups at home and receive tai­lor-made pre­ven­tion mea­sures for main­tain­ing one’s own health. Unique sell­ing points of Pre­ven­ti­cus include supe­rior bio-ana­lyt­i­cal algo­rithms backed by clin­i­cal evi­dence that make risk screen­ing pos­si­ble via smart­phone. Health part­ners can be net­worked with users and can mon­i­tor the app-gen­er­ated health pro­file and impact of the indi­vid­u­al­ized pre­ven­tion measures.


More infor­ma­tion about Pre­ven­ti­cus can be found under


About SiOp­tica

SiOp­tica GmbH was founded in 2013 in Jena, Ger­many with the goal to estab­lish inno­v­a­tive and spe­cial solu­tions in the mar­ket, pri­mar­ily in the field of optics. The com­pany offers tech­nolo­gies in the field of pri­vacy fil­ters that can pro­tect screen data from unau­tho­rized views with­out suf­fer­ing from asso­ci­ated bright­ness loss and can oper­ate in pub­lic or pri­vate modes. SiOptica´s solu­tions offer great advan­tages in the areas of ATM/Banking/Retail/Payment Ter­mi­nals, logistics/secure access, data secu­rity, as well as con­sumer electronics.

More infor­ma­tion about SiOp­tica can be found under


About bm‑t

Erfurt-based, bm‑t beteili­gungs­man­age­ment Thürin­gen (bm|t) – a sub­sidiary of the Thuringia Devel­op­ment Bank, is the first address for invest­ments in Thuringia, Ger­many. bm‑t cur­rently man­ages eight invest­ment funds with a total vol­ume of 320M EUR. bm‑t invests in inno­v­a­tive com­pa­nies with strong growth poten­tial across all sec­tors and all phases of the cor­po­rate lifecycle.

More infor­ma­tion about bm‑t can be found under‑

Back To Top
×Close search